🔗 Share this article

Given that America continues making historic adjustments to its vaccine recommendations, a particular individual has surfaced unexpectedly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by questioning Covid vaccines throughout the global health crisis and has concentrated on alleged fatalities after Covid immunization in her brief time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Program

Agency leaders were set to reveal major changes to the childhood vaccination calendar recently, bringing the US with Denmark’s vaccine program, according to reports – a major change that would place the US out of alignment with many the world with no evidence for improved outcomes. This reveal has been delayed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad consolidate power at the agency – and it points to a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has repeatedly called for discontinuing some childhood immunization guidelines in the US so as to align more in line with Denmark's approach, a nation with nationalized medicine and a citizenry about the size of Wisconsin’s.

To date statements, she has continued to focus on vaccines – usually the purview of Prasad, director of the FDA’s CBER – instead of medication approval.

Concerns Over Expertise

Dr. Høeg has no apparent background in medication creation, oversight or administrative roles, which has been typical for past heads of the CBER. She has served at the FDA as a key advisor to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in running a major agency. She has no expertise in drug approvals.”

Previous heads of CBER would “grasp laws and regulations and the underlying principles of medication creation”, said Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who led CBER have had.”

The drug center has an immense portfolio at the FDA, the former commissioner stated.

“Many people just focuses on the innovative therapies, but the off-patent medication office clears a multitude of generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and each of these need to be managed,” Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major management element to the position, which manages more than 5,000 staff members. “It is a massive administrative position, if you execute it properly,” Woodcock said.

Response and Controversial Initiatives

Regarding questions about Dr. Høeg's credentials and whether this assignment represents more teamwork among FDA leaders on vaccines, a press secretary stated that the “concerns are based on flawed assumptions”.

“Her experience aligns with the responsibilities of her job,” the official said, pointing to the time Høeg spent advising the agency head on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a disputed rapid drug-approval program that apparently troubled her preceding directors. “By what process are these therapies being chosen for this voucher program? Who takes the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he stated, “the agency seems to be moving towards laxer oversight of pharmaceuticals, aside from shots.”

Documented Track Record on Vaccines

With immunizations, Dr. Høeg has a more established, if problematic, past, critics have noted. She authored a study using unconfirmed volunteer-provided data to estimate the incidence of myocarditis after Covid vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccinations are more dangerous than they are.

Included in her “wish list” for the new government featured revising regulations for recently developed shots and ending “optional” vaccines, she said after the election on a online show. At the agency, Dr. Høeg has reportedly proposed barring teenage boys from obtaining Covid vaccines.

“She’s an complete ideologue who commences with her preconceived notions and tailors the evidence to fit the science in a highly misleading, dishonest fashion,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow dissenters, {like|